Organophosphate (OP) chemicals include pesticides such as parathion, and nerve gases such as sarin and soman and are considered major chemical threat agents. Acute OP exposure is associated with a cholinergic crisis and status epilepticus (SE). It is also known that the survivors of OP toxicity exhibit neurobehavioral deficits such as mood changes, depression, and memory impairment, and acquired epilepsy. Our research has focused on addressing the need to develop effective therapeutic agents that could be administered even after prolonged seizures and would prevent or lessen the chronic morbidity associated with OP-SE survival. We have developed rat survival models of OP pesticide metabolite paraoxon (POX) and nerve agent sarin surrogate diisopropyl fluorophosphate (DFP) induced SE that are being used to screen for medical countermeasures against an OP attack. Our research has focused on studying neuronal calcium (Ca 2+ ) homeostatic mechanisms for identifying mechanisms and therapeutics for the expression of neurological morbidities associated with OP-SE survival. We have observed development of a "Ca 2+ plateau" characterized by sustained elevations in neuronal Ca 2+ levels in OP-SE surviving rats that coincided with the appearance of OP-SE chronic morbidities. These Ca 2+ elevations had their origin in Ca 2+ release from the intracellular stores such that blockade with antagonists like dantrolene, carisbamate, and levetiracetam lowered OP-SE mediated Ca 2+ plateau and afforded significant neuroprotection. Since the Ca 2+ plateau lasts for a prolonged period, our studies suggest that blocking it after the control of SE may represent a unique target for development of novel countermeasures to prevent long term Ca 2+ mediated OP-SE neuropsychiatric comorbidities such as depression, anxiety, and acquired epilepsy (AE).
A major challenge for the National Institutes of Health's Countermeasures Against Chemical Threats (CounterACT) program is to identify target mechanisms that underlie the morbidity and mortality arising from exposure to threat agents and then to reverse or block these mechanisms with novel therapies to prevent or effectively treat their devastating outcomes (Jett, 2016) . This program has identified organophosphate (OP) chemicals as major chemical threat agents which includes pesticides such as parathion, and nerve agents such as sarin and soman (Jett and Yeung, 2010) . Given the similarity of OP pesticides to chemical warfare agents, weaponization of OP agents represents a major security concern (Foxell, 2002) . Indeed, both the civilian and military populations have been exposed to OP agents either intentionally or accidentally and, alarmingly their use has been on the rise in the past few years (Pérez-Peña and Barry, 2018; McCurry and Graham-Harrison, 2017; BBCNews, 2013; Hood, 2001; Tuite and Haley, 2013) .
Outside of the threat scenarios, OP poisoning is a major problem worldwide with approximately 3 million poisonings cases and 200,000 deaths annually (Gunnell et al., 2007) . Civilians could be exposed to OPs in many ways including occupational exposure, contaminated food and water, large scale and illegal application, and contaminated waste disposal sites (Mohanraj et al., 2014; Than, 2013; Alavanja and Bonner, 2012; Lisker et al., 2011; Ajdacic-Gross et al., 2008) . They have also been choice agents for suicidal attempts in developing nations (Mohanraj et al., 2014) . While most of these cases occur in developing nations, The Toxic Exposure and Surveillance System database maintained by the American Association of Poison Control Centers has recorded increasing cases of OP exposures and deaths over the last 10 years in developed nations (Gummin et al., 2017) . These incidents and occurrences emphasize that exposure to OPs is a current reality and that it is vital to develop effective countermeasures to mitigate their devastating consequences.
Approaches to treating OP exposure and improving survival
Following acute OP exposure, the currently approved therapy is designed to limit the spread of immediate symptoms known as the "cholinergic crises" (Eddleston et al., 2008; ChemicalHazardsEmergencyMedicalManagement, 2013) . This is typically characterized by increased fluid secretion and foaming of the mouth, followed by intense seizures that rapidly evolve into status epilepticus (SE), and then very quickly respiratory depression, bradycardia, and death (Bajgar, 2004) . These symptoms evolve from the effect of OP's on the enzyme acetylcholinesterase (AChE) which, rapidly increases synaptic availability of the neurotransmitter acetylcholine and produces the symptoms observed in this "cholinergic crises". The current mainstay of OP poisoning treatment uses the 3-drug approach: 1) atropine, a muscarinic antagonist, to dry the copious secretions in the airway, 2) pralidoxime or 2-PAM, an AChE reactivator that would help catalysis of accumulated synaptic acetylcholine, and finally 3) a benzodiazepine such as midazolam or diazepam to control the seizures. These approaches have been useful in lowering the acute mortality after OP exposure (Eddleston et al., 2008; ChemicalHazardsEmergencyMedicalManagement, 2013) .
Despite these advances, effectiveness of current treatments is limited to the acute care setting. In mass civilian OP exposures, when the first responders arrive at the scene, the immediate goal is to treat the cholinergic symptoms and control SE and prevent mortality. Given the effectiveness of current treatment it is hopeful that a significant proportion of exposed individuals will survive the OP exposure. Giving the treatment within 30-60 min after the initiation of SE is optimal time window because the longer the SE continues, the greater is the neuronal damage and increased risk of mortality (Towne et al., 1994) . However, it would be essentially impossible to treat all the victims in this window of opportunity for these agents to be effective. Given this reality, it is essential to develop innovative strategies to treat and possibly cure the chronic morbidities that will inevitably develop in many survivors of OP exposure (Steenland et al., 1994; Ruckart et al., 2004; Edwards and Tchounwou, 2005; Garcia et al., 2003) .
Our research has focused on addressing the need to develop effective therapeutic agents that could be administered even after prolonged SE and would prevent or lessen the chronic morbidity associated with OP SE survival (Deshpande et al., 2016a ). An animal model that would mimic both the acute and chronic effects of severe OP exposure could help in deciphering mechanisms underlying the development of chronic morbidities in OP exposed animals. This research effort has developed rat survival models of OP-SE that would mimic the human exposure condition where Emergency Medical Services (EMS) would arrive at 1 h after exposure (Deshpande et al., 2014a; Deshpande et al., 2010) .
Development of rat survival models of OP-SE
One of the many challenges in studying OP-SE in the laboratory is the high toxicity associated with these threat agents. Lethal exposure produces high mortality due to rapid progression of the cholinergic symptoms and complicates evaluation of long-term morbidities. Resolution of the different components of OP-induced cholinergic crises including the expression of SE is sometime masked due to complex pharmacokinetic and pharmacodynamic response of OP compounds. We have employed diisopropyl fluorophosphate (DFP) (Deshpande et al., 2010) that mimics symptoms of nerve agent such as sarin and soman exposures and the OP pesticide Parathion's metabolite paraoxon (POX) (Deshpande et al., 2014a) to develop rat SE survival models that would replicate both the acute mortality and chronic morbidity associated with these OP threat agents.
In these models, rats are injected sub-cutaneously with POX or DFP at 1.5× LD 50 concentration to mimic a lethal exposure. At 1-min. Following the OP exposure, rats are intra-muscularly injected with human-dose equivalents of atropine and 2-PAM. This prevents immediate mortality due to respiratory and cardiac disturbances and allows for the progression of next stage of symptoms marked by SE. This period for the appearance of Racine Stage-5 seizures is usually 7-10 min after OP exposure. Rats remain in SE for 1-h to mimic the delay associated with the arrival and treatment by the first responders in a mass casualty scenario. SE is then stopped with midazolam. The behavioral manifestations and EEG profiles in these models mimic the signs and symptoms of acute OP intoxication. Approximately 80% of rats survive lethal OP exposures following these methods allowing for a significantly greater number of animals for studying mechanisms for the development and expression of long-term OP-SE morbidities. Fig. 1 shows the paradigms for the POX and DFP SE survival models (Deshpande et al., 2014a; Deshpande et al., 2010) . These models are widely used by CounterACT investigators to identify novel neuroprotective agents for the treatment of OP toxicity (Wu et al., 2018; Scholl et al., 2018; Liang et al., 2018; Hobson et al., 2018) .
Neuronal injury and chronic behavioral morbidities in the rat survival models of OP-SE
For our OP-SE survival models to be truly reflective of not only the acute manifestations of OP intoxication, they should also display the chronic aftermaths of such survival. SE associated with chemoconvulsants or other chemical threat agents is associated with neuronal loss in critical brain regions (Deshpande et al., 2014a; Deshpande et al., 2010; Liang et al., 2018; Li et al., 2011; Turski et al., 1983) . Our OP-SE models also mirror these observations and display significant neuronal loss as assessed using the Fluoro Jade (FJC) labeling technique (Fig. 2) . We have observed a marked increase in FJC + neurons within the hippocampus, parietal cortex, amygdala and thalamic regions of OP SE rats (Deshpande et al., 2014a; Deshpande et al., 2010; Deshpande et al., 2016b) . Damages to these critical brain areas have been implicated in development of neurological co-morbidities ( These agents are prepared fresh in ice-cold PBS and kept on ice before their sub-cutaneous administration. One-minute later atropine sulfate and 2-PAM prepared in saline are injected intramuscularly. Rats start to show progression of cholinergic symptoms typified by vacuous chewing movement, salivation, Straub tail response, intense tremors and ultimately continues seizures (SE). From the appearance of first Stage-4 SE, rats are allowed to seize for 1-h at which point midazolam is injected to stop the SE. Surviving rats are injected with saline and sucrose-milk solution to aid their recovery. Test countermeasures are administered immediately after midazolam intervention. OP-SE survival, Ca 2+ estimations, and neuropathology are assessed during the first few weeks. Development of chronic morbidities are assessed at latent timepoints beginning at 3-months post OP-SE survival (models originally published in Refs: (Deshpande et al., 2014a (Deshpande et al., , 2010 .
L.S. Deshpande and R.J. DeLorenzo Neurobiology of Disease 133 (2020) 104418 Research by Dr. John McDonough's group at U.S. Army Medical Research Institute of Chemical Defense has shown that significant morbidity associated with OP SE survival is a consequence of SE and probably not due to OP exposure itself (Shih et al., 2007; Shih et al., 2003) . In the animal models of lethal OP intoxication, in the absence of immediate treatment with atropine and 2-PAM, death promptly ensues (Deshpande et al., 2014a; Deshpande et al., 2010) . Use of these initial therapies prevents immediate death and allows for the progression into SE. Most of the chronic morbidity that appears in the lethal OP survivors is likely related to SE. However, we cannot exclude some effects of OP on morbidity. Future studies evaluating blocking SE immediately by injecting midazolam along with other adjunct therapies would produce an OP exposure model without SE. These animals could be studied to address this issue.
As discussed earlier, survivors of OP intoxication suffer from mood and behavior disorders, depression, memory impairment and the development of acquired epilepsy (Steenland et al., 1994; Edwards and Tchounwou, 2005; Burns et al., 2013; Rosenstock et al., 1991; Savage et al., 1988) . To this end, we have tested both the POX and DFP SE survivors for chronic behavioral morbidities using a battery of rat behavioral assays that are predictive of such outcomes (Phillips and Deshpande, 2016; Deshpande et al., 2014b) . In agreement with the human data, our results have shown that the OP-SE surviving rats exhibit symptoms of helplessness or despair (Fig. 3A) , anhedonia (Fig. 3B ), and anxiety ( Fig. 3C ) all indicative of presence of chronic depression (Fig. 3 ). Furthermore, these rats had trouble navigating mazes, remembering novel objects (Fig. 3D) , and locations indicative of cognitive deficits (Fig. 3 ). In addition, OP-SE surviving rats also displayed spontaneous, recurrent seizures. Thus, our rat survival models of OP-SE recapitulated the clinical experience and exhibited not only the acute behavioral and EEG manifestations of OP intoxication but also the chronic behavioral co-morbidities of depression, anxiety, memory impairment, and acquired epilepsy (Deshpande et al., 2016a; Deshpande et al., 2014a; Deshpande et al., 2010; Deshpande et al., 2014b; Blair et al., 2016) .
Comparisons between POX and DFP SE models with nerve agent SE models
The DFP and POX models of OP-SE optimized in our laboratory share many similarities to sarin (GB) and soman (GD) models of OPnerve agent SE (Scholl et al., 2018; Myhrer et al., 2005; Myhrer et al., 2018; de Araujo Furtado et al., 2012) . In all of these models, a lethal intoxication is ensued using a 1.2 to 2× LD 50 dose of a nerve agent.
Fig. 2. Neuronal injury following POX induced SE.
A-D. Representative photomicrographs of Fluoro-Jade C (FJC) staining in the dentate gyrus-hilus region, parietal cortex, amygdala, and thalamus 2 days after POX SE. Scale bars, 200 μm. E. Quantitative analyses of FJC labeling. FJC positive cells indicative of neuronal injury were observed in hilus, thalamus and cortex of POX rats 48-h after SE termination. Control rats did not exhibit any FJC labeling. (*p < 0.05 compared to control, t-test, n = 4-6 rats). (Data originally published in Ref: (Deshpande et al., 2014a) .
While sub-cutaneous administration is the preferred route of exposure, whole-body vapor exposure (Grauer et al., 2008) and inhalational routes (Perkins et al., 2016) have also been used with nerve agents. Rats are immediately treated with a muscarinic antagonist such as scopolamine or atropine followed by an oxime such as pralidoxime or obidoxime or HI-6 to improve survival (Myhrer et al., 2018) . Similar to DFP and POX models, sarin and soman exposed rats undergo rapid transition to SE. Various anticonvulsants have been used to terminate OP-SE (Shih et al., 2007) . In our hands, with the POX model, a single administration of midazolam (2 mg/kg) provides reliable termination of electrographic SE. In the DFP model, breakthrough seizures are occasionally observed around 12-18 h after initial midazolam injection (Wu et al., 2018) .
Neuronal damage seen in the POX and DFP SE models mirrors the spatial and temporal distribution of brain damage following soman or sarin SE (Scholl et al., 2018; Shih et al., 2003; Myhrer et al., 2018; de Araujo Furtado et al., 2012) . Fluoro-Jade staining has been observed within the amygdala, piriform cortex, parietal cortex, thalamus, CA1, CA3 and dentate gyrus. Within the limbic system, hilar cells are particularly vulnerable to SE damage. Neuronal damage is also a function of duration of SE. With soman model, neuronal damage can be seen with < 1-h of SE (Myhrer et al., 2005) while, for sarin it is reported that animals in which seizure activity occurred for < 1-h following onset, there was no neuronal damage in the brain regions (Lazar et al., 2016) . Development of behavioral co-morbidities following survival from SE is seen across all OP agents. Commonly reported neurological and psychiatric morbidities include anxiety, depression, memory impairment, and recurrent spontaneous seizures (Myhrer et al., 2018; de Araujo Furtado et al., 2012; Lazar et al., 2016; de Araujo Furtado et al., 2010) .
Altered calcium homeostasis following survival of OP SE: The "Ca 2+ plateau"
A major interest of our research program has been studying role of altered Calcium (Ca 2+ ) homeostatic mechanisms following diverse brain injuries such as Traumatic Brain Injury (TBI), SE, and stroke (Nagarkatti et al., 2009a; Sun et al., 2008; Raza et al., 2004) . Survival from these brain injuries is associated with co-morbid conditions such as depression, mood alterations, cognitive deficits and development of acquired epilepsy in rodents (Turski et al., 1983; Groticke et al., 2008; Phillips and Deshpande, 2016; de Araujo Furtado et al., 2012; Abdel-Rahman et al., 2004; Mazarati et al., 2008) , and are also reported by OP-SE survivors (Steenland et al., 1994 In this paradigm, in phase-I rats are allowed to explore an arena with two-identical objects for a 3-min period. After 1-h delay, rats are re-introduced in the same arena now containing one novel object. Time spent by the rats exploring the two objects is recorded over a 2-min period. Adjoining graph shows quantitation of a NOR test suggestive of an impaired recognition memory in POX SE rats as displayed significantly less time spent exploring the novel object. All data expressed as mean ± SEM, *p < 0.05, t-test, n = 8 rats. (Data originally published in Ref: (Deshpande et al., 2014b) . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Ca 2+ ions are major second messengers that modulate neuronal signaling and synaptic strength critical for behavioral outputs and essential tasks such as learning and memory (Bengtson and Bading, 2012) . Aberrant Ca 2+ signaling has been observed in many neuropsychiatric disorders including Alzheimer's disease (Peng et al., 2012) , Parkinson's disease (Surmeier and Schumacker, 2013) , and depression (Galeotti et al., 2006) . Thus, studying Ca 2+ homeostatic mechanisms in OP-SE could yield valuable clues for the development and expression of OP-SE morbidities and provide novel molecular targets for identifying pharmacological therapies for their effective treatment.
We have demonstrated that SE causes protracted elevations in neuronal cytosolic Ca 2+ levels that lasted for many weeks following the termination of brain injuries in rodents (Raza et al., 2004) . Ca 2+ levels were above 300 nM for > 30-days and remained significantly elevated above the baseline for as long as 18-months after Pilocarpine SE (Raza et al., 2004) . In the OP-SE models, we have measured Ca 2+ elevations for up to 30-days post SE (Deshpande et al., 2014a; Deshpande et al., 2010) . We called these chronic elevations in intracellular Ca 2+ levels ([Ca 2+ ] i ) the "Ca 2+ plateau" (Nagarkatti et al., 2009b; DeLorenzo et al., 2005) . The Ca 2+ plateau has been demonstrated following SE in vivo (Raza et al., 2004) , in vitro (Nagarkatti et al., 2010) , after TBI (Sun et al., 2008) , and in excitotoxic injuries (Deshpande et al., 2007) . The Ca 2+ plateau in the pilocarpine model of SE has been shown to be pronounced in pyramidal principal neurons from the hippocampus in comparison to other brain regions, frontal, temporal and occipital cortex (Raza et al., 2004) . Using the low Magnesium (Mg 2+ ) model of SE in the hippocampal cultures, we also demonstrated the development of the Ca 2+ plateau (Nagarkatti et al., 2009b) .
Thus, it was important to determine if survival of rats from OP-SE was also associated with such a Ca 2+ plateau. Like the Ca 2+ homeostasis studies from our Pilocarpine-SE studies, POX and DFP OP-SE rats were sacrificed and hippocampal slices were acutely dissociated to obtain CA1 neurons at several time-points leading to one-month after SE. While, contributions of non-neuronal cells, the glia-especially astrocytes and microglia-in the pathophysiology of SE and epilepsy are significant (Devinsky et al., 2013) , this methodology allowed us to conduct pharmacological manipulations of Ca 2+ homeostatic mechanisms on multiple neurons imaged simultaneously without confounds of glia and slice variability. We measured neuronal [Ca 2+ ] i using the highaffinity, ratiometric Ca 2+ indicator Fura-2 in acutely isolated hippocampal neurons from naive control, sham, and OP-treated animals. Representative pseudocolor images of neurons from sham and DFPtreated animals are shown in Fig. 4A . Multiple acutely isolated CA1 hippocampal neurons harvested from animals that underwent 1-h POX or DFP-induced SE were quantitated for [Ca 2+ ] i (Fig. 4B ) and the average values were obtained for comparison studies (Fig. 4C) .
This approach provided a powerful method to evaluate the development of the Ca 2+ plateau in our rat survival models of OP-SE. These experiments revealed that following both POX and DFP SE, hippocampal [Ca 2+ ] i rose dramatically (Fig. 4A ). Furthermore, [Ca 2+ ] i remained significantly elevated for several weeks after SE and into the appearance of spontaneous recurrent seizures and chronic morbidities (Fig. 4C) . These experiments demonstrate that POX (Deshpande et al., 2014a) and DFP-induced SE (Deshpande et al., 2010) caused a Ca 2+ plateau lasting for weeks that was essentially identical to the Ca 2+ plateau produced by pilocarpine induced SE (Raza et al., 2004) . These results and other studies indicate that the development of Ca 2+ plateau could be a harbinger of OP-SE morbidities. Thus, inhibition of Ca 2+ plateau could prove to potentially be an effective mechanism to prevent and/or treat OP-SE morbidities.
Pharmacological blockade of the Ca 2+ plateau following survival of rats from OP-SE
In our attempt to understand the genesis and development of Ca 2+ plateau, we evaluated several Ca 2+ homeostatic mechanisms to determine their role in the maintenance of the Ca 2+ plateau. We systematically blocked the extracellular and intracellular mechanisms associated with Ca 2+ entry and release in the cell (Raza et al., 2001; Pal et al., 2001) . Our research indicated that Ca 2+ influx via the traditional mechanisms for Ca 2+ entry such as the voltage-gated Ca 2+ channels, ligand-gated N-methyl-D-aspartate receptors (NMDAR), or other Ca 2+ permeable channels were not contributing to Ca 2+ plateau, since pharmacological blockade of these mechanisms did not prevent the development of Ca 2+ plateau (Raza et al., 2001; Pal et al., 2001) . Since prolonged Ca 2+ influx did appear to mediate the Ca 2+ plateau, we evaluated intracellular regulators of Ca 2+ levels. The endoplasmic Fig. 4 . Development of the Ca 2+ plateau following OP-SE. A. Pseudo-color ratiometric images of representative acutely isolated hippocampal neurons from control, POX and DFP treated SE rats. Control neurons had bluish color that corresponds to lower Fura-2 ratio while OP-SE neurons had orange-red color that corresponds to higher Fura-2 ratio. B. Representative Ca 2+ imaging study providing quantitation of [Ca 2+ ] i in 6 acutely isolated neurons obtained from control and SE rats 24-h after POX SE injury. C. Hippocampal CA1 [Ca 2+ ] i from age-matched control (white bar) and POX rats were isolated 1-h and 1, 7 and 30 days after SE (black bars). [Ca 2+ ] i in POX-SE rats was significantly higher than control values at all the time-points and did not return to base-line even at 30-days post SE (Ca 2+ plateau). (Data originally published in Refs: (Deshpande et al., 2014a (Deshpande et al., , 2010 . (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) reticulum (ER) contributes to the overall levels of intracellular Ca 2+ by acting to either release or sequester Ca 2+ . Calcium that is stored in the ER can be released through activation of inositol triphosphate receptors (IP 3 R) or ryanodine receptors (RyR). These receptors sense the cytoplasmic Ca 2+ levels and mediate Ca 2+ induced Ca 2+ release (CICR) from the ER and can amplify the Ca 2+ signal that enters the cell (Berridge, 1998; Zucchi and Ronca-Testoni, 1997) . We have demonstrated that inhibition of IP 3 R and RyR can block the Ca 2+ plateau, since CICR inhibitors such as dantrolene (Nagarkatti et al., 2010) , and carisbamate (Deshpande et al., 2008) were able to block the Ca 2+ plateau and prevent the development of spontaneous, epileptiform discharges in an in vitro model of SE.
In OP-SE models, a similar mechanism for Ca 2+ plateau was observed. While the development of Ca 2+ plateau was dependent on initial Ca 2+ influx from NMDAR, the maintenance was independent of this mechanism. Indeed, NMDAR antagonist MK-801 given before OP-SE prevented the generation of Ca 2+ plateau but, when administered after 1-h of OP-SE, MK-801 treatment didn't lower neuronal Ca 2+ and was also unable to prevent the development of Ca 2+ plateau (Deshpande et al., 2010) (Fig. 5A and B) . Under these circumstances, CICR blockers proved to be most effective (Deshpande et al., 2014a; Deshpande et al., 2010) . Dantrolene (10 mg/kg, i.p.), carisbamate (90 mg/kg, i.p.), and levetiracetam (50 mg/kg, i.p.) injected at 1, 6 and 18-h following onset of SE were all effective in blocking the Ca 2+ plateau in OP models of SE (Fig. 5C ). These results provided the first evidence that it was possible to block or decrease the Ca 2+ plateau following OP-SE, allowing us to evaluate whether blocking the Ca 2+ plateau could prevent some of the morbidity associated with OP-SE. There is a possibility that some of the CICR inhibitors used in our studies could aid in effectively terminating OP-SE. Indeed, carisbamate and levetiracetam are known antiepileptic drugs. Our studies have shown that midazolam is effective in aborting electrographic OP-SE. Thus, inclusion of carisbamate or levetiracetam would play little role in stopping SE. However, it is possible that these agents may prevent breakthrough seizures once midazolam levels sufficiently drop in the body. One important point to consider is that dantrolene is not an antiepileptic agent and yet it is able to exert a strong neuroprotective effect when administered after OP-SE. This suggests that CICR inhibition and not an antiepileptic profile is the necessary requirement for neuroprotection in OP-SE.
Blockade of the Ca 2+ plateau provides neuroprotective effects following POX-SE
The hippocampus is susceptible to SE injury and neuronal damage is seen in CA1, CA2, CA3 and dentate gyrus regions following acute neurological insults. As discussed above, we see parallels in temporal and spatial patterns of neuronal injury between the pilocarpine and OP-SE models. In our POX model, cells in the dentate gyrus were found to be particularly vulnerable and therefore we evaluated neuroprotection in this region as a reliable measure of neuroprotective efficacy for our test therapeutic agents within the limbic system. We conducted experiments to determine if CICR inhibitors that blocked the Ca 2+ plateau would reduce the neuronal loss following OP-SE. Dantrolene (10 mg/ kg, i.m.) or carisbamate (90 mg/kg, i.m.) or appropriate vehicle was injected at 1-h and 6-h following onset of SE and then at 8:00 AM/ 6:00 PM the next day. Treatments with either carisbamate or dantrolene that blocked or reduced the Ca 2+ plateau (Fig. 5C ) significantly inhibited POX SE-induced hippocampal injury as identified by significantly lower FJC labeling in the hilar region of dentate gyrus, parietal cortex, thalamic, and amygdalar nuclei (Fig. 6) . These results suggest that agents that block the Ca 2+ plateau may represent effective counteract agents to reduce neuronal loss following survival of animals from OP-SE (Deshpande et al., 2016b) .
Neurodegeneration is one of many consequences of OP-induced SE. Survival from SE is associated with significant neuropsychiatric morbidities (Brooks-Kayal et al., 2013) and these changes could involve SE injury-induced transformation in myriad of processes including axonal sprouting, neurogenesis, astrocytes activation and changes in neurotransmitter release and their receptor response to name a few (Pitkanen et al., 2015) . Studies are needed to investigate whether these CICR inhibitor therapy also results in other beneficial effects on additional (Deshpande et al., 2014a (Deshpande et al., , 2010 .
consequences of OP-SE such as neuroinflammation, gliosis, blood-brain barrier leakage, angiogenesis, and mossy fiber sprouting.
Future directions
Using the POX and DFP survival models of OP-SE it would be possible to evaluate the effects of blocking the Ca 2+ plateau following SE on the development of chronic morbidities associated with OP SE. Inhibiting CICR with the therapeutic agents used here produces a significant blockade of the OP-SE Ca 2+ plateau. However, in the presence of these agents, cytoplasmic Ca 2+ doesn't completely restore to baseline levels. The remainder of the Ca 2+ plateau still present presumably represents Ca 2+ elevations from alterations in other Ca 2+ homeostatic mechanisms such activation of Na + Ca 2+ ATPase or decreases in the Ca 2+ buffering mechanisms. We have reported on these observations in pilocarpine SE models (DeLorenzo et al., 2005) . Further studies are needed investigate contributions of these other mechanisms towards Ca 2+ homeostasis in the context of OP-SE. We could evaluate chronic behavioral and cognitive deficits in these models (Deshpande et al., 2014b) . In addition, continuous video/EEG monitoring can be employed to evaluate the development of acquired epilepsy after OP SE (Blair et al., 2016) . Utilizing the DFP and POX models of OP exposure to test the effects of agents on preventing the development of depression cognitive changes and Acquired Epilepsy (AE) will be an important future direction for research (Deshpande et al., 2016a) . While our SE studies were conducted in adult male rats, additional studies are needed to investigate the role of gender (Pitkanen et al., 2014) and age (Scholl et al., 2018) on response to DFP and POX induced behaviors and effects of CICR inhibitors.
The DFP and POX models are being used to identify additional mechanisms for OP-SE morbidities and develop novel therapies for the treatment of OP toxicity (Wu et al., 2018; Scholl et al., 2018; Liang et al., 2018; Hobson et al., 2018) . This is an important area of research that has direct translational implications for clinical treatment. Targeting the Ca 2+ plateau represents a novel approach to developing counteract agents to address the chronic morbidity associated with OP-SE. Since the Ca 2+ plateau lasts for a prolonged period, our studies suggest that blocking it after the control of SE may represent a unique opportunity to prevent long term Ca 2+ mediated morbidities. A. Representative photomicrographs of Fluoro-Jade C (FJC) staining in the dentate gyrus-hilus region, parietal cortex, amygdala, and thalamus of a POX rat 2 days after POX SE, and POX + dantrolene (10 mg/kg, i.m.), and POX + carisbamate (90 mg/kg, i.m.) treated rats. Scale bars, 200 μm. Dantrolene or carisbamate were administered 60-mins post POX SE and resulted in a minimum of approximately 60% reduction in FJC labeling across all the regions analyzed. B. Quantitative analyses of FJC labeling. Control rats did not exhibit any FJC labeling. FJC positive cells indicative of neuronal injury were observed in hilus, amygdala, thalamus and cortex of POX rats 48-h after SE termination. Rats treated with dantrolene or carisbamate showed significantly less FJC labeling in these brain regions (*p < 0.05 compared to control, t-test, n = 6 rats). Dantrolene was obtained from Sigma Chemical Company and was dissolved in saline. Warm water sonication for about 10 min was needed to get the drug in solution. Carisbamate was provided by Johnson & Johnson (Pharmaceutical Research & Development L.L.C., Titusville, NJ, U.S.A.) and was dissolved in sterile water made slightly basic with sodium hydroxide. Levetiracetam was obtained in injectable form (Hospira Company). (Data originally published in Ref: (Deshpande et al., 2016b) .
